ÂÜÀòÂÒÂ×

Chris Leidel is a seasoned business development executive with extensive experience in the biotechnology and engineering sectors. Currently serving as Vice President of Business Development at Standard BioTools since April 2022, Chris previously held leadership roles including Director of Business Development at the same company, Head of Cell and Gene Therapy Strategy at MilliporeSigma from October 2019 to April 2022, and Chief Strategy Officer at FloDesign Sonics, which was acquired by MilliporeSigma in 2019. Earlier in the career, Chris served as VP of Business Development at The Grommet, Project Manager, COO, and Co-Founder at Therapeutic Systems, M&A Associate at United Technologies, and Design Engineer at Texas Instruments/Sensata Technologies. Educational credentials include an MBA from Isenberg School of Management, UMass Amherst, and a BS in Mechanical Engineering from the University of Massachusetts Amherst.